BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Actavis clocks $8.7 bn revenue in 2013

21 February 2014 | Company results | By BioSpectrum Bureau

Singapore: Global pharmaceutical company Actavis has clocked net revenue of $8.7 billion in the year 2013, marking an increase of 47 percent as compared to net revenue of $5.9 billion for full year in 2012.

The company made $2.79 billion in the fourth quarter ending December 2013, marking a leap by 59 percent as compared to $1.75 billion in the fourth quarter of 2012.

"2013 was Actavis' most successful year ever, highlighted by our acquisition of Warner Chilcott and our accelerated evolution into a premier, global specialty pharmaceutical leader. With the announcement earlier this week of our intention to acquire Forest Laboratories, we begin 2014 well-positioned to further our evolution by creating an innovative new model in specialty pharmaceuticals leadership, with the ability to continue delivering sustainable, long-term organic growth," said Mr Paul Bisaro, chairman and CEO, Actavis.

"In our branded pharmaceuticals business, growth during 2013 was driven by strong sales of core products in the US, including the Rapaflo and Generess Fe franchises, which saw double digit prescription growth on a year-over-year basis. We also saw key product approvals in several markets around the world, including Oxytrol OTC and Crinone eight percent in the US, Fibristal and LoLo in Canada, Rapaflo in Brazil and Levosert in the UK and additional European countries.

"Growth in our US generic business was driven by strong product launches of generic versions of Suboxone Sublingual tablets, Lidoderm and Cymbalta. In our international business we launched 674 products and experienced strong growth across all of our key markets."

"Exceptional productivity in our industry leading Research & Development (R&D) organization resulted in the record filing of 53 Abbreviated New Drug Applications (ANDAs) in the US and more than 750 applications globally, including an industry-leading first-to-file portfolio. We confirmed 18 new first-to-file applications in the US last year, highlighting the remarkable execution within our R&D team. We also continued to record progress in our biosimilar initiatives, both internally and through our ongoing collaboration with Amgen, with three products: biosimilar Herceptin, biosimilar Avastin and rFSH now in phase III trials."